March 10 (Reuters) - Neogenomics Inc NEO.O:
NEOGENOMICS EXPANDS ONCOLOGY TESTING REACH IN THE NORTHEAST WITH ACQUISITION OF PATHLINE
NEOGENOMICS INC: SYNERGIES FROM TRANSACTION EXPECTED TO YIELD ANNUAL COST REDUCTIONS, WHICH WILL BE ACCRETIVE TO AEBITDA STARTING IN 2026
Source text: ID:nBw2qLyq7a
Further company coverage: NEO.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。